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The metabolic syndrome (MS) is a set of metabolic disturbances, represented by various cardiovascular risk factors which are
generally associated with the central accumulation of fat and the resistance to insulin. Inadequate changes in eating behaviours and
weight loss, which are associated to taking part in regular physical activity, are considered to be primary and first choice therapies for
the treatment of MS, as they assist in the reduction of the abdominal girth and visceral fat, improve the sensibility to insulin and reduce
the plasmatic concentrations of glucose and triglycerides, raise the values of high density lipoproteins and, consequently decrease
the risk factors which contribute to the development of type 2 diabetes. The MS is a current discussion theme in the health field as it is
related to illnesses/diseases, which not only cause a worldwide high mortality rate but show increasing incidence. Type 2 diabetes is
characterised by a deregulation of the carbohydrates, lipids and proteins found in the metabolism and result in diminished secretion
of insulin, resistance to insulin or a combination of both. Type 2 diabetes is the most form of diabetes of the first 3 types of diabetes,
representing 90% of all cases. Diabetes is a chronic and complex disease which requires a strict medical follow-up so as to reduce
the risks and obtain strategies for its control. The fast-epidemiological global evolution which has been registered in the last few years,
leads to it being considered one of the pandemics of the 21st century. In this non-systematic and advanced review of theMS in type 2
diabetic patients, several articles were consulted, and some recently published studies were analysed.
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In the 9th edition of the International Diabetes Federation (IDF)
Diabetes Atlas, the prevalence of diabetes is estimated in 2019
and projected for 2030 and 2045. It is estimated that there are
463.0 million cases of diabetes among adults between the ages of
20 and 79 including both type 1 and type 2 worldwide1 (Fig. 1).
Based on the estimates for 2019 regarding adults between 20
and 79 years old, the projected figure for 2030 is 578.5 million,
rising to 700.2 million in 2045 he numbers of patients who will
live with diabetes (Table 1).
It is estimated that in 2019, 463 million people will have
diabetes and that number is expected to reach 578 million
until 2030 and 700 million until 2045. More than 4 million
people, between the ages of 20 and 79 died of diabetes related
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other words until the age of 19) living with diabetes increases
annually. Another cause for alarm is the high percentage of
undiagnosed diabetes, presently over 50% and being predomi-
nantly type 2 diabetes cases. There are situations that people
with a set of risk factors, essentially cardiovascular, have more
chance to develop cardiovascular disease (heart attack and
stroke) and diabetes. This finding is called metabolic syndrome
(MS).
The MS does not give symptoms and its only sign is the
presence of a prominent abdomen. This syndrome affects more
than a third of the adult Portuguese population. Thus, the
necessity for urgent diagnosis of people who are undiagnosed
with diabetes, and the need to offer adequate and timely
treatment to all diabetes sufferers.2
Based on the facts presented, this study aims to gather
information about MS and diabetes in order to contribute to the
identification of an accurate diagnosis and ensure a better quality
of life for patients, focusing on the development of more effective
treatment options.
Metabolic syndrome
The first formal definition for MS occurred during a discussion
about diabetes among a group of World Health Organization
(WHO) consultants in 1998. At the time, the question of
resistance to insulin was highlighted as being the main risk, and
the need to have a clinical proof of the fore mentioned resistance
for the diagnosis.3,4 Consequently, the IDF published a globally
recognised and accepted definition of MS in 2006. In the
document, MS is defined as a set of cardiovascular and as a new
epidemic.5
The Joint Scientific Declaration, published in 2009, character-
ises the MS as a complexity of risk factors related to the
cardiovascular system and diabetes mellitus.3
Figure 1. Total estimated number of adults (20- to 79-year-old) with diabetes in 2019. Source. IDF Diabetes Atlas, 9th Edition.
Regufe et al Porto Biomed. J. (2020) 5:6 Porto Biomedical JournalIt may be referred, that among the main comorbidities which
are known and associated with the MS may be found among
individuals who have abdominal obesity and show resistance to
insulin. These 2 conditions are strongly related with the
occurrence of metabolic risk factors.
Some studies3,5,6 refer that obesity and resistance to insulin are
fundamental causes of this syndrome, highlighting that central
obesity, which is characterised by the concentration of fat in the
abdominal region, is highly associated with MS. Central obesity
may also be involved with the development of type 2 diabetes and
the risk of cardiovascular diseases. According to the world
consensus of MS, the causes are resistance to insulin and central
obesity, however, both conditions may be associated with other
clinical conditions such as atherosclerosis, overweight and type 2
diabetes.1,5,7
The diagnosis of MS can be made when at least 3 factors of the
following 5 are present: abdominal obesity—abdominal circum-
ference that exceeds 102cm inmen and 88cm in women indicates
excess abdominal fat, triglycerides equal to or >150mg/dl, highTable 1








Men 240.1 9.6 296.7
Women 222.9 9.0 281.8
Source. IDF Diabetes Atlas, 9th Edition.
2
density lipoproteins (HDL) cholesterol equal to or <40mg/dl in
men and 50mg/dl in women, blood pressure equal to or>135/85
mm Hg, and fasting blood glucose equal to or >100mg/dl.3
MS is considered to be a public health concern due to its
growing prevalence. Several scientists have alerted to a greater
awareness of people’s lifestyles, where the National Health
System of every country is concerned. In clinical terms, the focus
is on identifying and reducing the risk factors which are
associated with the MS, including people’s lifestyles.Epidemiology of the metabolic syndrome
In 2006, the prevalence of the MS was between 20% and 25%
worldwide and was already considered as one of the most
common chronic diseases, placed fourth in the list of the main
causes of death in the whole world.5
A narrative review of the literature available in 20148 showed
that the global prevalence of MS varied from 10.0% to 84.0%,












Figure 2. Prediction of increase in diabetes worldwide. Source. IDF Diabetes
Atlas, 9th Edition.
Regufe et al Porto Biomed. J. (2020) 5:6 www.portobiomedicaljournal.comfactors, among which are age and body mass index. These varied
from 5.0% (eutrophic) to 60.0% (obese), as well as 10.0% (20-
to 29-year-old) to 45.0% (60- to 69-year-old), respectively.8
In developed European countries the prevalence of MS is high.
In this context, an European study analysed 8 cohorts (total:
8200 men and 9363 women) researching the frequency of MS
according to the WHO’s criteria and compared the data with an
alternative proposed definition of MS for non-diabetic individu-
als. The study concluded that the prevalence of MS varies from
7.0% to 36.0% in men between the ages of 40 and 55, and from
5.0% to 22.0% among women in the same age bracket, although
a progressive increase that was directly proportional to the
increase in age was noticed for both genders, the percentage was
higher among men than women in many cases.9
Further to cardiovascular diseases and type 2 diabetes, the MS
is also considered a risk factor for strokes and kidney diseases.10
A study published in the National Health and Nutrition
Examination Survey (NHANES) 50, which was carried out in
the USA between 1999 and 2010, analysed on a temporary basis
the prevalence of MS in adults. Although the analysis showed a
decline in the prevalence of MS in the USA, changes in its
components were evident among the population, as was the case
of abdominal obesity, which was a growing tendency in the
whole population since the start of the study.
Another systematic review which was published in 2013
concerning the prevalence of MS in Brazil, covering 10
publications since 2006 to 2012, showed the average prevalence
varied from 28.9% to 29.6% due to the criteria for diagnosing
MS. The lowest rate was a result of using the National
Cholesterol Education Program Adult Treatment Panel III
(NCEP ATP III) criteria. When adjustments were made according
to age, the average prevalence was 22.0%, rising to 41.3% when
it was adjusted by gender.11Metabolic syndrome and type 2 diabetes
MS has been associated with type 2 diabetes due to its high
prevalence worldwide since it is both related to the increase in
obesity and a sedentary lifestyle. Several studies suggest thatTable 2










High-income countries 10.4 (8.6–13.3)
∗
95.2 (78.7–120.9) 11.4 (9.4–
Middle-income countries 9.5 (7.6–12.3) 353.3 (280.1–455.3) 10.7 (8.4–
Low-income countries 4.0 (2.8–6.7) 14.5 (10.0–24.3) 4.3 (3.0–
∗
95% confidence intervals are reported in brackets.
Source. IDF Diabetes Atlas, 9th Edition.
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individuals with MS are 5 times more likely to develop type 2
diabetes.3,12,13
Type 2 diabetes is a rising global health problem. Individuals
with type 2 diabetes are at higher risk of microvascular
complications (including retinopathy, nephropathy and neurop-
athy) and macrovascular complications (such as cardiovascular
diseases and other comorbidities), due to hyperglycaemia and
individual components of insulin resistance (IR). Environmental
factors also contribute to the multiple physiopathological
disturbances responsible for the decrease of glucose homeostasis
in type 2 diabetes.14
Diabetes as an important health problem has reached alarming
levels. Nowadays, almost half a billion people are living with
diabetes worldwide1 (Fig. 2).
Epidemiology of diabetes
Type 2 diabetes corresponds to a percentage that ranges from
90.0% to 95.0% of the cases of diabetes which do not require
insulin treatment.15
In a great majority of developed countries, diabetes is the main
cause related to cardiovascular diseases and other complications.
The total number of cases of diabetes in the world has been
increasing noticeably, and in 30 years the global prevalence of
diabetes has become 12 times greater, a rise which was mostly
due to new cases of type 2 diabetes.16
In an update of the IDF World Atlas of Diabetes, the data
gathered from 220 countries and territories shows that in 2015
the prevalence of diabetes among adults between the ages of 20
and 79 was approximately 8.8%, which corresponds to about
415million people. From that total number, only 25.0%are from
developed countries, while the remaining results are from
emerging and underdeveloped countries. According to the Atlas,
the estimate for 2040 is more than 600 million people or 1 in
every 10 adults will suffer from diabetes.7
Presently, there are 351.7 million working people between the
age of 20 to 64, who have been either diagnosed or not diagnosed
with diabetes in 2019. This figure should increase considerably to
417.3 million until 2030 and to 486.1 million until 2045. The
greatest rise will occur in regions where the economies are
evolving from low earnings to average earnings (Table 2).
The age range in which diabetes is more prevalent globally is
among 60- to 79-year-old (18.6%), a group where a greater
growth, proportional to the cases, is expected. However,
quantitatively, there is a greater number of cases in the 40 to
59 age brackets. The majority of the cases of diabetes occurs in
low to average income, where a greater increase proportional to
the cases is expected. Further to the rise of the economic income,
there is an inverse proportional growth, in other words, the lower










14.3) 107.0 (88.3–134.4) 11.9 (9.8–14.8) 112.4 (92.2–139.2)
13.7) 449.6 (353.0–576.7) 11.8 (9.0–15.0) 551.2 (422.7–705.2)
7.1) 21.9 (15.2–36.4) 4.7 (3.3–7.9) 36.5 (25.8–60.2)
Regufe et al Porto Biomed. J. (2020) 5:6 Porto Biomedical JournalThe lack of glucose control contributes to the high figures
which are associated to the prevalence of the disease, which
according to the American Diabetes Association, 33.0% to
49.0% of diabetes is due to sufferers failing to reach the goals for
glucose control, blood pressure and cholesterol.15 Other factors
worth referring to are: the person having 2 or more diseases,
social and financial hardships as well as specific challenges to
reach the proposed objectives in the treatment of diabetes.
The global cost for the treatment and prevention of the
complications of diabetes has been estimated, in a conservative
analysis, to be 673 billion dollars, or according to a more open
analysis, the figure rises to 1197 billion dollars. It is forecasted that
thisfigurewill have risen from802 to1425billion dollars in 2040.7Pathophysiology of diabetes
The most recent publications describe the pathophysiology of
diabetes as being different between type 1 and type 2. A review
about the pathophysiological and pathogenic mechanisms of
diabetesmade in 2013 showed findingswhich evidence differences
between these 2 types of diabetes. Another narrative review which
covers classification, pathophysiology, diagnosis andmanagement
of diabetes made in 2015 also supports this information.18,19
Individuals with type 2 diabetes present identifiable circulating
insulin levels. An oral glucose tolerance test enables a thorough
separation of the different metabolic characteristics.18,19 There
are individuals who have normal glucose tolerance; others with
impaired or lower glucose tolerance, and they can be stratified as
a chemical diabetic group. Those individuals whose hyper-
glycaemia present values lower than 140mg/dl have diabetes with
mild fasting hyperglycaemia; and over that value, it is classified as
diabetes associated with evident fasting hyperglycaemia.18
When a tolerance result is identified, simultaneous damaged
glucose and high plasma insulin levels, it is a clear biochemical
proof of IR. By progressing from intolerance to diabetes, since
insulin levels decrease, the characteristic of the decrease of
secretion of that hormone in type 2 diabetes is reinforced, a trait
which is commonly evident in the majority of patients with
diabetes (type 2).18,19Figure 3. Pancreatic cells. Source. Ty
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The pathophysiology of type 2 diabetes involves a variable
combination of IR (mainly in the liver and muscles) and a
decrease in insulin secretion by pancreatic beta cells. Both can be
influenced by genetic and environmental factors. Furthermore,
other alterations can be related to the pathophysiology of type 2
diabetes, highlighting the dysregulation of hormonal secretion in
entero-hypothalamic and entero-insular axes, reflecting, in this
case, the multifactorial nature of the disease.20
The beta cell’s incapacity of responding to the increasing
demand of peripheral insulin, observed during the progressive
evolution of IR in glucose intolerant individuals, is nowadays
accepted as a determining phenomenon in the development of
diabetes. With this in mind, all the patients with type 2 diabetes
have measurable beta cell dysfunction, since the magnitude of the
IR after its onset slightly increases with time, however, on the other
hand, deterioration of beta cell function is progressive, leading to a
progressive loss of therapeutic response from the beta cells.21
During the evolution of IR, it is observed a progressive increase
in basal insulin concentrations in the blood, namely in obese
individuals. This increase can be maintained in some people,
while others lose it. The former will stay normoglycemic and
insulin resistant, whilst the latter will definitely lose the capacity
of maintaining the glucose homeostasis.22
The ectopic fat deposition has better prognosis as well as amore
important role in the development of IR if compared to deposition
and evaluation of visceral fat. This happens because muscle and
hepatic cells, full of fat, suffer interference in their normal
metabolism. The metabolite of triglycerides is capable of
influencing insulin signalling, glucose transport, phosphorylation
and muscular glycogen synthesis as well as the increase of hepatic
gluconeogenesis.23
Insulin is a hormone produced by pancreatic beta cells (Fig. 3),
which synthesis is activated when there is an increase of plasma
levels of glucose and amino acids, having an effect in several
tissues, particularly in muscles, liver and adipose tissue.24
In spite of IR being potentially seen as the main cause, insulin
deficiency can also be considered the primary cause, since
moderate IR is not enough to effectively induce type 2 diabetes.
Furthermore, the majority of the people diagnosed with thispe 1 Diabetes For Dummies, 2008.
Regufe et al Porto Biomed. J. (2020) 5:6 www.portobiomedicaljournal.comdisease have both situations. Due to presenting lighter symp-
tomatology, several individuals happen to detect type 2 diabetes
when complications are already evident.
Resistance to insulin
In non-diabetic population, the resistance to insulin may be
associated with metabolic/cardiovascular alterations, which
comprise: systemic arterial hypertension, hypertriglyceridemia,
reduction ofHDL-c (high density lipoproteins), increase of LDL-c
(low density lipoproteins), intolerance to carbohydrates, centrip-
etal obesity, increase of PAI-1, hyperuricemia and atherosclerotic
cardiovascular disease. This set of alterations is known as MS. In
view of these associations it is important to assess the sensitivity
to insulin. The assessment may be divided into direct or indirect
methods. The direct methods analyse the effects of a set quantity
of insulin injected into an individual. On the other hand, the
insulin action may be evaluated through the effect of endogenous
insulin, mainly in homeostasis conditions.
The indirect methods consist of: fasting insulinemia, homeo-
stasis model assessment (HOMA), HOMA-Adiponectinemia
(HOMA-AD), QUICKI (Quantitative Insulin Sensitivity Check
Inbox, Oral Glucose Tolerance Test (OGTT), and Frequent
Sample IV Glucose Tolerance Test (FSIVGTT).
In the absence of the above-mentioned methods, there are
complementary means to assess IR, namely: ATIC (Average
thickness of internal carotid), hormones, enzymes, inflammatory
markers, coagulation factors, anthropometric indicators and
body composition. The last 2 assess the individual’s phenotype
and may be clustered according to the type of obesity being
assessed: central or generalized.25
Complications of diabetes
Generically, diabetes can result in several complications
associated with organs and tissues such as the heart, blood
vessels, eyes, kidneys and nerves (eg, retinal lesion or physical
disability due to lower limb amputation).26
One of the many complications associated with diabetes is
hypoglycaemia. When blood glucose levels are under 70mg/dl, it
is considered severe hypoglycaemia and if they are under 40mg/
dl, a hypoglycemic crisis is considered diabetic ketoacidosis,
being more common in type 1 diabetes, but which can be fatal.27
Diabetic retinopathy, which is common in type 1 and 2
diabetes, is a microvascular complication which frequently leads
to blindness in adults and it can be related to the duration of
diabetes, hypertension, hyperglycaemia and nephropathy.28
Another common complication is kidney failure and the
association with diabetes makes it easier for its clinical evolution
towards dialysis. Diabetic Kidney Disease (DKD) is the main
triggering factor of end-stage kidney disease. In type 2 diabetes,
the DKD marker is albumin-to-creatinine ratio, which represents
an excellent cardiovascular risk factor in a 3 to 1 ratio.16,28
Diabetes also presumes the development of several diseases
such as non-alcoholic fatty liver disease, periodontal disease,
hearing loss, erectile dysfunction, depression, difficulty in
conceiving or during pregnancy.26
Every patient with diabetes presents a few metabolic risks
which need intervention whether in their lifestyle or medication
administration. Hyperglycaemia which has diabetic glucose
levels is one of the 5 criteria associated with MS diagnosis both
by National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) and IDF. The majority of people with
type 2 diabetes fit in the criteria associated with MS.3,165
Conclusion
The majority of the studies included in this review reveal that MS
is a cluster of disturbances which, once associated with other
pathologies, causes severe alterations in the human body that
affects namely patients with type 2 diabetes.
Some studies also refer that people with a recent diagnosis of
diabetes can be “seen” with this syndrome since it can affect both
the newly diagnosed diabetics and those who have been diagnosed
for longer. Therefore, it depends on the type of comorbidities that
eachperson has.Closely related to this is the duration of diabetes, a
factorwhich can ease the emergence ofMS,whether at a quicker or
a slower rate, due to the several comorbidities associated with,
including cardiac and vascular problems.
It can be taken into consideration that the environment which
surrounds the individual (eg, place of residence or geographic area)
can be favourable to this kind of pathology. In addition to the
environment, other characteristics canbe taken into account suchas
labour andworkingconditions,hygiene, social conditions, amongst
others.
Supporting this line of thought, it can be concluded that
socioeconomic status, provided by the environment and the
lifestyle of our population, namely European, is a risk factor for
cardiovascular diseases and other comorbidities, mainly MS.
In some systematic reviews, different methods were used, in
terms of evaluation of MS. One of them classified these methods
in terms of relevance in a hierarchical manner: first NCEP ATP III
(2001), followed by a modified version of 2005 (AHA/NHLBI),
then WHO (1998), and, at last, a modified version of WHO
(1999). In the researchmade, the described diagnosis criteria used
both for type 2 diabetes and MS possibly contribute to the high
heterogeneity between these pathologies.
Comparing individual components ofMS in individuals from a
type 2 diabetes sample, obesity is more common in women than
men as well as hypertension, uncontrolled hyperglycaemia, high
levels of triglycerides and LDL-c and low levels of HDL-c. The
same authors say that such alterations increase with age in this
particular population, becoming a potential factor for cardio-
vascular risk factors.
Globally, it is observed the importance of a holistic and non-
fragmented vision, not only when it comes to diabetes but also to
the cluster of comorbidities to which it may be associated with,
including MS.
It is suggested the development of more studies about this
topic, similar to the ones made in oriental and developing
countries, in order to evaluate and compare health conditions,
disease and epidemics. It would also be interesting to evaluate the
possible cultural influence of each continent and its population on
the prevalence of the disease.Conflicts of interest
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